StreetAlpha.app
Home › Stocks › MANE

Veradermics, Inc (MANE)

Healthcare
$125.89
▼ −1.69%
LAST CLOSE · NOV 17

Veradermics develops VDPHL01, an oral, non-hormonal treatment for hair loss, from its base in New Haven, Connecticut. It last closed at $125.89 on Nov 17, down 1.69% on the day. The average 12-month price target from 4 analysts is $175.25 (+39.2% from the last close), with a high of $204.00 and a low of $150.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $1.2M.

AI Auto Pilots
Is MANE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$93.6M
Free cash flow
−$82.6M
Valuation
Market cap
$5.3B
42.2M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$132.2M
At Sep 30
Shareholder equity
$796.5M
Shares outstanding
42.2M
At Nov 5
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2024: −$26.5M−$26.5MFY2024FY2025: −$70.0M−$70.0MFY2025

From MANE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on MANE in the past 90 days
Average 12-month target
$175.25
▲ 39.2% upside

Based on 4 analysts who set a price target on MANE in the past 90 days. The average target is $175.25, with a high of $204.00 and a low of $150.00, compared with the last close of $125.89.

Low $150.00Avg $175.25High $204.00
Blue marker: last close $125.89
Highest target$204.00
Average target$175.25
Lowest target$150.00
Latest rating changes
CitigroupTarget raised
Nov 10Buy$160 → $175
Leerink PartnersMaintained
Nov 9Buy$150
B. Riley SecuritiesTarget raised
Oct 22Buy$170 → $204
NeedhamTarget raised
Oct 19Buy$164 → $172
CitigroupTarget raised
Jul 16Buy$135 → $160
DateFirmActionRatingPrice target
Nov 10CitigroupTarget raisedBuy$160 → $175
Nov 9Leerink PartnersMaintainedBuy$150
Oct 22B. Riley SecuritiesTarget raisedBuy$170 → $204
Oct 19NeedhamTarget raisedBuy$164 → $172
Jul 16CitigroupTarget raisedBuy$135 → $160
Loading…

Technical Analysis

MANE · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. Momentum is fading (RSI 46). The nearest support is the swing low (Nov 5) at $125.40, and the nearest resistance the Pivot at $126.73.

Short trendNeutral
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 7.4%/day
Key levels
$156.6952 week high+24.5%
$137.6720 day average+9.4%
$129.80Swing high (Jul 15)+3.1%
$128.97Pivot R1+2.4%
$126.73Pivot+0.7%
$125.89Last close
$125.40Swing low (Nov 5)−0.4%
$123.65Pivot S1−1.8%
$123.2550 day average−2.1%
$116.54100 day average−7.4%
$32.0052 week low−74.6%
Indicators
RSI (14)45.84Middle of its rangeNeutral
MACD2.67Below its signal lineBearish
Stochastic8.8Near the bottom of its rangeOversold
ADX (14)22.3Weak trend
Williams %R-95.6Oversold below −80, overbought above −20Oversold
CCI (20)-151.8Oversold below −100, overbought above 100Oversold
Rate of change−5.5%Change over 10 sessionsBearish
ATR (14)$9.29Typical daily range, 7.4% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200–
What happened before, for MANE

What happened before

See how MANE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in MANE in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.8M
Largest print
$1.2M
Loading…

MANE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲136 buying vs 70 selling
  • ▲Held by funds +5.5 pts
  • ▲Funds holding +43
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding208165+26.1%
In funds' top 1068−25.0%
Held by funds86.3%80.8%+5.5 pts
New / increased60 / 7695 / 42−0.7%
Reduced / sold out53 / 1719 / 14+112.1%
Put/call ratio0.73––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MANE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MANE is in one of them and how their past MANE trades turned out.

MANE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MANE in an article yet. Here's the latest on the wider market.

About Veradermics

Veradermics is a biopharmaceutical company based in New Haven, Connecticut, that is developing treatments for hair loss. Its main product in development, VDPHL01, is an oral, extended-release form of minoxidil, a drug already used to grow hair, and it is designed to be non-hormonal. The company is running clinical trials in men and women with this condition and does not yet have an approved product. Its target customers are patients with hair loss and the dermatologists who treat them.

Headquarters
New Haven, CT